Professor Geert Leroux-Roels, Centre for Vaccinology, Ghent University and Hospital, Belgium and colleagues report on an “antigen sparing adjuvant strategy”, which, by combining the vaccine with an oil-in-water emulsion “adjuvant”, allows the body to produce up to six times as many bird influenza virus neutralising antibodies as it would with an non-adjuvanted vaccine with the same dose.
The bird flu strain H5N1 is widely regarded as the probable cause of the next global influenza pandemic. This virus contains a H5 haemagglutinin antigen subtype, which generally produces a poor immunogenic response in humans and to which most of the world population is immunologically naïve. As a result, the one-dose schedule routinely used for seasonal “regular” influenza vaccines is unlikely to be sufficient to give immunity. The authors say: “Clearly, new formulations that require less antigen per dose are needed. The use of adjuvant to improve immunogenicity is a crucial antigen-sparing strategy.”
The researchers did a study of eight groups of 50 volunteers aged 18-60 years, and studied four antigen doses (3.8µg, 7.5µg, 15µg, 30µg haemagglutinin) given with or without the oil-water adjuvant. Blood samples were then collected to analyse the immune response, and the results showed that the adjuvanted formulations were significantly more immunogenic than the non-adjuvanted formulations at all doses. All eight vaccine formulations had good safety profiles, although the adjuvanted vaccines produced more injection-site symptoms and general symptoms (most of which were mild to moderate and transient) than the non-adjuvanted vaccines.
The authors say that the ability of the 3.8µg dose of the adjuvanted vaccine to induce cross-immunity against the clade two* H5N1 Indonesia strain in more than the three-quarters of individuals with neutralising titres which are six times higher than the non-adjuvanted formulation “represents significant antigen sparing that could increase the number of recipients of the pandemic influenza vaccine.”
They conclude: “The cross-clade neutralising antibody responses recorded imply that such a vaccine could be deployed before pandemic outbreak, which is an important mitigation strategy proposed for pandemic influenza.”
In an accompanying Comment, Dr Suryaprakash Sambhara, Centers for Disease Control and Prevention, Atlanta, Georgia, USA and Dr Gregory Poland, Mayo Clinic and Foundation, Minnesota, USA, say: “Leroux-Roels and colleagues’ study is the first to show significant antigen dose-sparing, high levels of immunogenicity in association with a novel adjuvant, and the induction of cross-clade immunity against A/H5N1 viruses. Their study lends support for considering a strategy of immunising some groups with prepandemic vaccines for preparedness in the event of a pandemic from an H5N1 virus. This vaccine appears to be an important step forward in our ability to protect against the pandemic threat posed by highly pathogenic influenza A/H5N1 viruses.”
Tony Kirby | alfa
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy